expresspharmaOctober 19, 2020
Tag: AztraZeneca , Acalabrutinib 100 mg capsules , Calquence , oncology drug
AstraZeneca Pharma India has received import and market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100 mg capsules (Calquence ). AstraZeneca Pharma India intends to launch Calquence in India on October 21, 2020.
Acalabrutinib 100 mg capsules (Calquence ) is:
Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: